Olakino
Investment Thesis & Opportunity
Solving the massive, costly, and growing global diabetes epidemic using innovative, targeted wellness solutions. The opportunity is to provide a highly affordable and effective alternative to the devastating costs of diabetes management; the app costs the user only $50 per year, dramatically contrasting with the $9,600/year total cost of diagnosed Type 2 Diabetes per person. The Total Addressable Market is 1.1 Billion users. The immediate market focus (short term) is the European Union, followed by North America (medium term), with a final expansion to a Global long-term market.
Business Model, Market Opportunity, & Strategy
The business operates on a Subscription Model, offering monthly plans at $5.99/Month and annual plans at $49.99/Year. The core offering is the Olakino Health Trainer, a complete exercise app that uses AI to tailor exercises by collecting and analyzing biometrics from wearable devices (like the Apple Watch and Abbott Libre). The Go-to-Market Strategy is partnership-driven, focusing on close co-operation with insurance companies and large businesses for distribution, alongside forming partnerships with Diabetes Associations. The product roadmap involves achieving Medical Device type IIa Certification in the US (FDA) and EU (MDR) by June 2026, positioning it as a clinically validated therapeutic tool. Wearable device manufacturers can target people with diabetes, when they add Olakino HT with their product offering
Financial Performance, Terms, & Target Returns
Olakino is seeking to raise €1.5 million to secure a 15-month runway. The funding allocation is heavily weighted toward growth, with Development Costs accounting for the largest share at 31%, followed by Payroll Expenses at 23% and Marketing at 14%. Financial projections show aggressive growth after initial launch, with Total Revenue forecasted to surge from $1 Million in Year 2 to $46 Million by Year. Profitability is projected to be robust, with EBITDA climbing to $5 Million in Year 4 and reaching $24 Million by Year 5.
Impact Measurement, Management, & SDG Alignment
Management Team & Corporate Governance
The Management Team is a well-rounded mix of business and medical experts from Finland, including Pauliina Kario (Founder & CEO), a CTO & AI Development lead, and three professors specializing in medicine: Professor of Biomedical Engineering (Dr. Tapio Seppänen), Professor of Physiology (Dr. Mikko Tulppo), and Professor of Cardiology (Dr. Juhani Junttila).
Risk Factors & Exit Strategy
The company outlines a clear Exit Strategy with three potential paths: an IPO (building a public-ready company), a Sale/Acquisition (targeting a larger corporation or competitor), or Secondary Market Sales
TV Episode
Podcast
